{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:31:48Z","timestamp":1772109108204,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.lungcan.2017.12.008","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T03:14:47Z","timestamp":1513221287000},"page":"62-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["Intracerebral efficacy and tolerance of nivolumab in non\u2013small-cell lung cancer patients with brain metastases"],"prefix":"10.1016","volume":"116","author":[{"given":"Cl\u00e9ment","family":"Gauvain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enora","family":"Vaul\u00e9on","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Jabot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florent","family":"Vinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis Benjamin","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2017.12.008_bib0005","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non\u2013small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2016.12.041","article-title":"Immunotherapy revolutionises non\u2013small-cell lung cancer therapy: results, perspectives and new challenges","volume":"78","author":"Giroux Leprieur","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2017.12.008_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminoncol.2017.01.001","article-title":"Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1. 1-defined disease progression in clinical trials","volume":"44","author":"Kazandjian","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fonc.2017.00038","article-title":"Current Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer","volume":"7","author":"Melosky","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0030","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0035","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non\u2013small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0045","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non\u2013small\u2013cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2017.12.008_bib0050","first-page":"32","article-title":"Temporal and gender-related trends in brain metastases from lung and breast cancer","volume":"86","author":"Yawn","year":"2003","journal-title":"Minn. Med."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0055","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the Graded Prognostic Assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0060","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1468-1331.2006.01506.x","article-title":"EFNS guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force","volume":"13","author":"Soffietti","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10147-009-0916-1","article-title":"The role of chemotherapy in the treatment of patients with brain metastases from solid tumors","volume":"14","author":"Walbert","year":"2009","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0070","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1183\/09031936.00195609","article-title":"Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation","volume":"37","author":"Porta","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0075","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/annonc\/mds529","article-title":"Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)","volume":"24","author":"Wu","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0080","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1023\/A:1008338312647","article-title":"Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: groupe Fran\u00e7ais de Pneumo-Cancerologie (GFPC) Protocol 95-1","volume":"12","author":"Robinet","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0085","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jtho.2015.10.024","article-title":"A brief report of the status of central nervous system metastasis enrollment criteria for advanced non-small cell lung cancer clinical trials: a review of the ClinicalTrials.gov Trial Registry","volume":"11","author":"McCoach","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.12.008_bib0090","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2016.05.031","article-title":"Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases","volume":"98","author":"Dudnik","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2017.12.008_bib0095","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non\u2013small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."}],"updated-by":[{"DOI":"10.1016\/j.lungcan.2018.10.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000}}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217306153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217306153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:23:13Z","timestamp":1759234993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217306153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":19,"alternative-id":["S0169500217306153"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.12.008","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracerebral efficacy and tolerance of nivolumab in non\u2013small-cell lung cancer patients with brain metastases","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}